<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108857</url>
  </required_header>
  <id_info>
    <org_study_id>2110/2021</org_study_id>
    <nct_id>NCT05108857</nct_id>
  </id_info>
  <brief_title>PET Imaging of Systemic Sclerosis Using FDG and 68Ga-DOTA-Siglec-9 9</brief_title>
  <acronym>SYSPET</acronym>
  <official_title>PET Imaging of Systemic Sclerosis Using 18F-FDG and 68Ga-DOTA-Siglec- 9</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the potential of positron emission tomography (PET)/computed tomography&#xD;
      (CT) imaging to monitor disease activity in patients with systemic sclerosis (SSc). PET/CT&#xD;
      imaging will focus on two pathological features of SSc, i.e. metabolic activity evaluated by&#xD;
      glucose analog 18F-FDG, and expression of inflammation-inducible vascular adhesion protein 1&#xD;
      (VAP-1) evaluated by 68Ga-DOTA-Siglec-9 tracer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with systemic sclerosis (SSc), the quantitative assessment of disease activity is&#xD;
      still difficult. Identification of patients who unlikely respond to therapy before or early&#xD;
      in a course of the treatment could reduce morbidity and produce cost-savings. This project&#xD;
      will evaluate the potential of advanced functional imaging techniques to monitor disease&#xD;
      activity. Functional imaging will focus on two pathological features of SSc, i.e. metabolic&#xD;
      activity evaluated by glucose analog 18F-FDG positron emission tomography (PET)/computed&#xD;
      tomography (CT), and expression of inflammation-inducible vascular adhesion protein 1 (VAP-1)&#xD;
      evaluated by new 68Ga-DOTA-Siglec-9 tracer. If successful, the resulting techniques may prove&#xD;
      invaluable as tools in the clinical practice and in drug research aiming to find new targets&#xD;
      to the treatment of SSc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of inflammation in PET/CT images</measure>
    <time_frame>Day 1</time_frame>
    <description>Standardized uptake value of PET tracer at the sites of inflammation</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Systemic Sclerosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin biopsies Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of Turku University Hospital or Kuopio University Hospital with active systemic&#xD;
        sclerosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with active systemic sclerosis (SSc).&#xD;
&#xD;
          -  Onset of SSc (defined as first non-Raynaud symptom) not more than 5 years ago.&#xD;
&#xD;
          -  Clinically active disease with proximal nailfold capillary abnormalities detected with&#xD;
             videocapillaroscopy and/or raised inflammatory markers (CRP or ESR).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underage, pregnant, breastfeeding, handicapped or prisoner&#xD;
&#xD;
          -  History of or current inflammatory joint disease or autoimmune disease other than SSc.&#xD;
&#xD;
          -  History of treatment with, prior to this study, immunosuppressives or&#xD;
             disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, leflunomide,&#xD;
             azathioprine, mycophenolate, cyclophosphamide or biologic agents such as anti-TNF&#xD;
             inhibitors, abatacept, or rituximab. Hydroxychloroquine is allowed in the history (≥3&#xD;
             months prior to PET study).&#xD;
&#xD;
          -  Intra-articular or parenteral corticosteroids ≤4 weeks prior to PET/CT study.&#xD;
&#xD;
          -  Prostanoids or other vasoactive treatments like phosphodiesterase-5 inhibitors or&#xD;
             endothelin receptor antagonists ≤4 weeks prior to PET/CT study (the use of calcium&#xD;
             channel inhibitors is allowed).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Roivainen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital, Turku PET Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Roivainen</last_name>
    <phone>+3582313000</phone>
    <email>pet@tyks.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turku University Hospital, Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Roivainen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

